Silencing of Insulin-like Growth Factor-1 Receptor Enhances the Radiation Sensitivity of Human Esophageal Squamous Cell Carcinoma in Vitro and in Vivo

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2014 Nov 4

PMID 25363593

Citations 9

Authors

Hui Zhao

Xiaomeng Gu

Affiliations

Soon will be listed here.

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is a prevalent fatal cancer worldwide, and the number of deaths due to this disease is increasing. Due to ESCC resistance to chemotherapy and radiation treatment, new therapies are urgently needed for the improvement of ESCC patient clinical outcomes.

Methods: Eca-109 and TE-1 cells were transfected with 100 nM IGF-1r siRNA, and a combination of IGF-1r siRNA and radiation therapy was tested in vitro and in vivo. The effects of IGF-1r siRNA were determined through Western blotting and flow cytometry experiments.

Results: After radiotherapy, the number of IGF-1r siRNA-transfected Eca-109 cells decreased by approximately 67.3%, and a 78.9% reduction was observed in the transfected TE-1 cells. In addition, the Eca-109 and TE-1 cells that were irradiated following IGF-1r knockdown contained 16.2% and 20.3% apoptotic cells, respectively.

Conclusions: The results of the current study suggest that IGF-1r knockdown may enhance the radiation sensitivity of ESCC and increase the therapeutic effects of radiation both in vitro and in vivo. These results provide strong evidence that the targeted application of siRNA will enable the development of new therapeutic strategies for the clinical treatment of ESCC patients.

Citing Articles

Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma.

An L, Li M, Jia Q Mol Cancer. 2023; 22(1):140.

PMID: 37598158 PMC: 10439611. DOI: 10.1186/s12943-023-01839-2.

MALAT1 knockdown inhibits hypopharyngeal squamous cell carcinoma malignancy by targeting microRNA-194.

Wang H, Wang F, Ouyang W, Jiang X, Li W Oncol Lett. 2020; 20(1):173-182.

PMID: 32565945 PMC: 7285813. DOI: 10.3892/ol.2020.11551.

Therapeutic Targeting of the IGF Axis.

Osher E, Macaulay V Cells. 2019; 8(8).

PMID: 31416218 PMC: 6721736. DOI: 10.3390/cells8080895.

Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.

Toulany M Genes (Basel). 2019; 10(1).

PMID: 30621219 PMC: 6356315. DOI: 10.3390/genes10010025.

Insulin-like growth factor-1 receptor knockdown enhances radiosensitivity via the HIF-1α pathway and attenuates ATM/H2AX/53BP1 DNA repair activation in human lung squamous carcinoma cells.

Liu X, Chen H, Xu X, Ye M, Cao H, Xu L Oncol Lett. 2018; 16(1):1332-1340.

PMID: 30061953 PMC: 6063047. DOI: 10.3892/ol.2018.8705.

References

Wang X, Tian L, Tian J, Li D, Wang Y, Wu H . Overexpression of Cks1 increases the radiotherapy resistance of esophageal squamous cell carcinoma. J Radiat Res. 2012; 53(1):72-8. DOI: 10.1269/jrr.11090. View

Bellini M, Silva A, Varella-Garcia M . Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques. Genet Mol Biol. 2011; 33(2):205-13. PMC: 3036856. DOI: 10.1590/S1415-47572010005000028. View

Luo M, Shen D, Zhou X, Chen X, Wang W . MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery. 2013; 153(6):836-47. DOI: 10.1016/j.surg.2012.12.004. View

Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y . Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 2006; 28(5):947-56. DOI: 10.1093/carcin/bgl247. View

Li S, Huang E, Lu H, Huang W, Yen C, Huang W . Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2012; 144(6):1352-9, 1359.e1. DOI: 10.1016/j.jtcvs.2012.06.049. View

Nakajima M, Kato H . Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother. 2013; 14(10):1345-54. DOI: 10.1517/14656566.2013.801454. View

Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y . Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 2012; 18(18):5144-53. DOI: 10.1158/1078-0432.CCR-12-0701. View

Sukka-Ganesh B, Mohammed K, Kaye F, Goldberg E, Nasreen N . Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene. BMC Cancer. 2012; 12:309. PMC: 3488573. DOI: 10.1186/1471-2407-12-309. View

Arcaro A . Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol. 2013; 4:30. PMC: 3605519. DOI: 10.3389/fphar.2013.00030. View

10.

Fernandez M, Martin A, Venara M, de Lujan Calcagno M, Sanso G, Quintana S . Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2013; 79(5):623-30. DOI: 10.1111/cen.12205. View

11.

Adachi Y, Ohashi H, Imsumran A, Yamamoto H, Matsunaga Y, Taniguchi H . The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma. Tumour Biol. 2013; 35(2):973-85. DOI: 10.1007/s13277-013-1131-2. View

12.

Thallinger C, Kiesewetter B, Raderer M, Hejna M . Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res. 2012; 32(11):4609-27. View

13.

Xie L, Song X, Yu J, Wei L, Song B, Wang X . Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs. J Exp Clin Cancer Res. 2009; 28:68. PMC: 2694165. DOI: 10.1186/1756-9966-28-68. View

14.

Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K . Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One. 2013; 8(1):e54048. PMC: 3554755. DOI: 10.1371/journal.pone.0054048. View

15.

Stoner G, Wang L, Chen T . Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol. 2007; 224(3):337-49. PMC: 2128258. DOI: 10.1016/j.taap.2007.01.030. View

16.

Kwong D, Cao T, Hu Q, Zhang L, Ming X, Chen J . Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus. 2013; 28(1):84-9. DOI: 10.1111/dote.12088. View

17.

Shang L, Wang M . Molecular alterations and clinical relevance in esophageal squamous cell carcinoma. Front Med. 2013; 7(4):401-10. DOI: 10.1007/s11684-013-0286-y. View

18.

He L, Liu M, Li B, Rao H, Deng H, Guan X . Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009; 100(9):1591-6. PMC: 11158532. DOI: 10.1111/j.1349-7006.2009.01224.x. View

19.

Doyle S, Donohoe C, Finn S, Howard J, Lithander F, Reynolds J . IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol. 2011; 107(2):196-204. DOI: 10.1038/ajg.2011.417. View

20.

Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J . Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013; 23(4):233-42. PMC: 3709543. DOI: 10.2188/jea.je20120162. View